Adverse events in women switching from olaparib capsules to tablets: retrospective observational study of US claims data

Written by The Evidence Base

In this Publication Perspective, watch lead study author Susana Banerjee (Institute of Cancer Research, London, UK) discuss research she was recently involved in concerning adverse events in women switching from olaparib capsules to tablets. In this Publication Perspective, originally published in the Video Journal of Biomedicine, lead study author Susana Banerjee (Institute of Cancer Research, London, UK) discusses research she was recently involved in, published in Future Oncology, concerning adverse events in women switching from olaparib capsules to tablets. In the study, real-world US claims data on patients who have switched from olaparib capsules to tablets were analyzed to provide insight into the tolerability...

To view this content, please register now for access

It's completely free